Shots:

• Edwards Lifesciences has agreed to acquire JenaValve Technology and Endotronix for a total upfront payment of ~1.2B, strengthening its structural heart portfolio
• The acquisition of JenaValve Technology will add the JenaValve Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high-risk patients to Edwards’ portfolio. Edwards expects the system’s FDA approval in late 2025
• The acquisition of Endotronix will add an implantable pulmonary artery pressure sensor, Cordella, intended for heart failure management to the company’s portfolio. CMS national coverage determination is anticipated during early 2025

Ref: Edwards Lifesciences | Image: Edwards Lifesciences

Related News:- BD Reports the Acquisition of Edwards Lifesciences' Critical Care Product Group, Enhancing its Smart Connected Care Solutions

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com